Our data suggest that HCQ is of therapeutic benefit in SLE because its use is associated with impairment of the in vivo production of IFN-α and TNF-α by circulating pDCs upon stimulation of TLR-9 and TLR-7. The gene discussed is TLR7; the disease is systemic lupus erythematosus.